Valuation Picture: A Slight Discount to Industry P/E
The current P/E of 36.46 for Sun Pharmaceutical Industries Ltd represents a modest discount of approximately 2.5% relative to the industry average of 37.40. This suggests that despite its large-cap stature and strong market presence, the stock is not commanding a significant premium over its peers. Such a valuation level may reflect investor caution amid recent volatility or a more conservative outlook on near-term earnings growth. The sector’s average P/E itself is elevated, indicative of the premium often accorded to pharmaceutical companies given their growth prospects and defensive qualities. Previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating? The valuation premium or discount is a key factor in this reassessment.
Performance Across Timeframes: Divergent Momentum
Examining the stock’s returns across multiple timeframes reveals a mixed momentum profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 20.24% gain, significantly outperforming the Sensex’s 3.54% loss during the same period. This outperformance extends to the three-month horizon, where the stock rose 6.43% compared to the Sensex’s 2.95%. However, the one-month return tells a different story, with the stock declining 3.65%, underperforming the Sensex’s 1.42% fall. The one-week and one-day performances also show slight underperformance, with the stock down 0.18% versus the Sensex’s 0.36% decline today, and a 0.35% gain versus the Sensex’s 0.50% loss over the week. This divergence suggests recent profit-taking or short-term headwinds despite a generally positive medium-term trend — is this a temporary correction or a sign of deeper weakness?
Moving Average Configuration: Mixed Technical Signals
The technical picture for Sun Pharmaceutical Industries Ltd is characterised by a nuanced moving average configuration. The stock price currently sits above its 100-day and 200-day moving averages, signalling that the longer-term trend remains intact. However, it trades below the 5-day, 20-day, and 50-day moving averages, indicating short-term weakness or consolidation. This pattern often reflects a recent pullback within an overall uptrend, suggesting that while the stock has experienced some near-term selling pressure, the broader technical backdrop remains constructive. The 100-day and 200-day averages act as key support levels, and the stock’s ability to hold above these could be critical for sustaining momentum — is this a genuine recovery or a relief rally that will fade at the 50 DMA?
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Sector Context: Mixed Results in Pharmaceuticals & Biotechnology
The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 34 stocks that have declared results, 14 reported positive outcomes, 15 were flat, and 5 posted negative results. This distribution suggests a sector grappling with varied operational and market challenges, including regulatory pressures, pricing dynamics, and innovation cycles. Within this context, Sun Pharmaceutical Industries Ltd’s ability to outperform the Sensex over multiple timeframes is notable. However, the recent short-term underperformance relative to the sector and market indices indicates that the company is not immune to sector-wide headwinds — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?
Rating Context: Previously Rated Hold, Now Reassessed
On 25 Aug 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from a previous Hold rating. While the current rating is not disclosed, the reassessment reflects a comprehensive review of the company’s fundamentals, valuation, and technical indicators. The Mojo Score of 74.0 and large-cap market capitalisation of ₹4,59,868.54 crores underpin the company’s significant market presence. The rating change coincides with the stock’s recent price action and valuation metrics, suggesting a recalibration of expectations by analysts and investors alike.
Want to dive deeper on Sun Pharmaceutical Industries Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Collective Data Insights: Balancing Valuation and Momentum
The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a valuation closely aligned with its industry peers, while exhibiting strong medium- to long-term performance relative to the Sensex. The recent short-term underperformance and mixed moving average signals suggest a period of consolidation or correction within an otherwise constructive trend. The sector’s mixed results further underscore the challenges facing the industry, making the stock’s relative resilience noteworthy. What does the current rating imply for investors navigating this complex landscape?
Price and Market Capitalisation Snapshot
As of the latest trading session, Sun Pharmaceutical Industries Ltd opened and traded at ₹1,901, with a marginal day decline of 0.18%, slightly underperforming the sector’s day performance by 0.76%. The company’s large-cap status is reinforced by its market capitalisation of ₹4,59,868.54 crores, placing it among the dominant players in the Pharmaceuticals & Biotechnology sector.
Long-Term Performance: A Strong Track Record
Looking beyond the recent year, the stock has delivered impressive returns over longer horizons. The three-year return stands at 72.32%, more than triple the Sensex’s 18.74% gain. Over five years, the stock has surged 141.35%, vastly outperforming the Sensex’s 33.76% rise. However, the ten-year return of 147.36% trails the Sensex’s 170.57%, reflecting periods of relative underperformance in the distant past. This long-term data highlights the company’s capacity for sustained growth, albeit with phases of volatility and market cycles.
Conclusion: A Data-Driven Perspective on Sun Pharmaceutical Industries Ltd
The valuation and performance data for Sun Pharmaceutical Industries Ltd reveal a stock that balances a near-industry-average P/E with strong medium- and long-term returns. The recent short-term weakness and mixed technical signals suggest caution, but the overall trend remains positive. The sector’s mixed results and the company’s large-cap stature add further context to this complex picture. Investors may find value in analysing these data points carefully — should they hold, buy more, or reconsider their position?
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
